Novo Nordisk A/S
Thesis
Novo Nordisk has disrupted the diabetes treatment market with its GLP-1 drugs, which have created a larger market opportunity despite impacting its own insulin business. The company has consistently generated strong financial results over the past 20 years and continues to innovate, making it a compelling long-term investment.
Did it work?
The thesis's core factual claims largely materialized: Novo Nordisk's GLP-1 franchise (Ozempic/Wegovy) created a substantially larger diabetes and obesity market opportunity, and the company delivered strong revenue and earnings growth, at one point becoming Europe's most valuable company. However, no price performance or elapsed time is provided, so the actual investment return cannot be verified, and subsequent competitive pressures introduce uncertainty. Since the judgment rests on thesis events rather than measured returns, confidence is low.